Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

NAGE Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Niagen Bioscience IncNASDAQ: NAGE

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $19.98M rose 3.3% year over year, behind the +24.3% change in trailing-twelve-month gross profit. Sequentially, it fell 8.0% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.

Context

  • Gross profit amounted to 64.3% of revenue in FY2025, up 2.4 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.3% toward the trailing-twelve-month pace of +24.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.98M-8.0% QoQ
Last fiscal yearDec 2025
$83.19M+35.1% YoY
LTMMar 2026
$83.83M+24.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%——
1 year+35.1%——
3-year CAGR+24.8%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
83.19M USD
Year-over-year change
+35.1%
4-year CAGR
+19.0%

Gross Profit vs competitors

How NAGE compares with its peers on the latest reported figures

  • NAGE's LTM Mar 2026 gross profit of $83.83M is the 5th highest of the 10 companies compared; the peer median is $32.01M.
  • Its year-over-year change of +24.3% is the 4th highest of 7, against a peer median of -20.3%.
  • Gross profit amounts to 64.3% of revenue for NAGE, versus a peer median of 85.5%.
NAGE Competitors Peer median
Gross Profit for NAGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$279.95M +53.8%+32.3%93.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$187.95M +39.8%-10.0%80.9%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$106.66M ——92.0%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$104.57M +226.8%+108.4%85.5%
NAGENiagen Bioscience IncLTM Mar 2026$83.83M +24.3%+24.8%64.3%
KROSKeros Therapeutics, Inc.LTM Mar 2026$32.01M -85.0%—96.5%
PRTAProthena Corporation plcLTM Mar 2026$27.14M -80.3%-51.9%46.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K ———
RGNXREGENXBIO Inc.LTM Mar 2026-$120K -100.1%+37.2%0.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$306K ———
Peer median (excluding NAGE) $32.01M-20.3%+32.3%85.5%

Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue67.45M72.05M83.57M99.6M129.42M
Cost of Revenue25.96M29.25M32.79M38.01M46.23M
Gross Profit41.49M42.8M50.78M61.59M83.19M
Gross Margin61.5%59.4%60.8%61.8%64.3%
Research & Development3.83M4.83M4.96M6.02M6.33M
Selling, General & Admin64.73M56.6M51.42M47.84M62.56M
Operating Expenses68.56M61.43M56.38M53.86M68.89M
Depreciation & Amortization1.63M1.88M1.71M1.48M1.45M
EBITDA(25.45M)(14.66M)(3.23M)10.34M19.64M
EBITDA Margin-37.7%-20.3%-3.9%10.4%15.2%
Operating Income(27.07M)(18.63M)(5.6M)7.73M14.3M
Operating Margin-40.1%-25.9%-6.7%7.8%11.0%
Interest Income03K661K1.13M2.13M
Interest Expense55K0000
Other Income / Expenses(55K)2.09M661K1.13M3.9M
Income Before Tax(27.13M)(16.54M)(4.94M)8.86M18.19M
Pre-Tax Margin-40.2%-23.0%-5.9%8.9%14.1%
Income Tax Expense000305K810K
Net Income(27.13M)(16.54M)(4.94M)8.55M17.38M
Net Margin-40.2%-23.0%-5.9%8.6%13.4%
EPS (Basic)(0.40)(0.24)(0.07)0.100.22
EPS (Diluted)(0.40)(0.24)(0.07)0.110.20
Weighted Avg Shares67.19M68.92M70.54M85.42M79.18M
Weighted Avg Shares (Diluted)67.19M69.73M74.99M79.72M85.44M

Niagen Bioscience Inc

NASDAQ:NAGE

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.